Clinical Trial Update: IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating neoadjuvant therapy for resectable stage IB-III non-squamous non-small cell lung cancer, comparing IBI-363 plus chemotherapy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IBI-363
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING